In diabetic patients, metformin caused a 50% reduction in HCC incidence and improved survival mainly by influencing cell growth and angiogenesis through the PI3K/AKT/mTOR signaling pathway (91). This evidence concerns the gene MTOR and hepatocellular carcinoma.